Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carles Pericay

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Journal of the National Cancer Institute|July 5, 2023
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402David Pesántez, Sanne Ten Hoorn, Isidro Machado, et al.
The Oncologist|August 22, 2018
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline ImatinibCésar Serrano, Xavier García-Del-Muro, Claudia Valverde, et al.
Cancers|September 28, 2021
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS StudyPilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, et al.
British Journal of Cancer|August 3, 2017
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer RegistryPaula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 24, 2020
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Eva Martínez de Castro, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 2, 2021
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM RegistryFelipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Journal of the National Cancer Institute|July 5, 2023
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402David Pesántez, Sanne Ten Hoorn, Isidro Machado, et al.
The Oncologist|August 22, 2018
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline ImatinibCésar Serrano, Xavier García-Del-Muro, Claudia Valverde, et al.
Cancers|September 28, 2021
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS StudyPilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, et al.
British Journal of Cancer|August 3, 2017
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer RegistryPaula Jiménez Fonseca, Alberto Carmona-Bayonas, Raquel Hernández, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 24, 2020
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Eva Martínez de Castro, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 2, 2021
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM RegistryFelipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, et al.
Pageof 7